<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioorg Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">Bioorg. Med. Chem. Lett</journal-id><journal-title-group><journal-title>Bioorganic &#x00026; Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="ppub">0960-894X</issn><issn pub-type="epub">1464-3405</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7331567</article-id><article-id pub-id-type="publisher-id">S0960-894X(20)30488-1</article-id><article-id pub-id-type="doi">10.1016/j.bmcl.2020.127377</article-id><article-id pub-id-type="publisher-id">127377</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The SARS-CoV-2 main protease as drug target</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Ullrich</surname><given-names>Sven</given-names></name></contrib><contrib contrib-type="author" id="au010"><name><surname>Nitsche</surname><given-names>Christoph</given-names></name><email>christoph.nitsche@anu.edu.au</email><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005">Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. <email>christoph.nitsche@anu.edu.au</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>2</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>2</day><month>7</month><year>2020</year></pub-date><volume>30</volume><issue>17</issue><fpage>127377</fpage><lpage>127377</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="ab005"><title>Graphical abstract</title><fig id="f0040" position="anchor"><graphic xlink:href="ga1_lrg"/></fig></abstract><abstract id="ab010"><p>The unprecedented pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening global health. The virus emerged in late 2019 and can cause a severe disease associated with significant mortality. Several vaccine development and drug discovery campaigns are underway. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. Sequence and structure of the main protease are closely related to those from other betacoronaviruses, facilitating drug discovery attempts based on previous lead compounds. Covalently binding peptidomimetics and small molecules are investigated. Various compounds show antiviral activity in infected human cells.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>Protease inhibitors</kwd><kwd>Peptidomimetics</kwd><kwd>Antivirals</kwd></kwd-group></article-meta></front><body><sec id="s0005"><title>Introduction</title><p id="p0005">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 (coronavirus disease 2019) pandemic. Globally, 10 million infections have been confirmed with 500,000 fatalities.<xref rid="b0005" ref-type="bibr"><sup>1</sup></xref> The novel coronavirus had first been reported in Hubei province of China in late 2019, where it caused a major cluster of atypical pneumonia.<xref rid="b0010" ref-type="bibr">2</xref>, <xref rid="b0015" ref-type="bibr">3</xref>, <xref rid="b0020" ref-type="bibr">4</xref> Despite major efforts to contain the original outbreak, SARS-CoV-2 has since spread worldwide.<xref rid="b0025" ref-type="bibr">5</xref>, <xref rid="b0030" ref-type="bibr">6</xref>, <xref rid="b0035" ref-type="bibr">7</xref>, <xref rid="b0040" ref-type="bibr">8</xref> Following the 2002/2003 SARS and 2012 MERS (Middle East respiratory syndrome) epidemics, this marks the third notable coronavirus outbreak in the 21<sup>st</sup> century.<xref rid="b0030" ref-type="bibr">6</xref>, <xref rid="b0045" ref-type="bibr">9</xref>
</p><p id="p0010">Four additional coronaviruses can infect humans, HCoV-229E, HCoV-HKU1, HCoV-NL63 and HCoV-OC43,<xref rid="b0050" ref-type="bibr"><sup>10</sup></xref> which in stark contrast to the highly contagious and pathogenic SARS-CoV, MERS-CoV and SARS-CoV-2,<xref rid="b0035" ref-type="bibr">7</xref>, <xref rid="b0055" ref-type="bibr">11</xref>, <xref rid="b0060" ref-type="bibr">12</xref> cause only mild respiratory illness like the common cold.<xref rid="b0065" ref-type="bibr"><sup>13</sup></xref> The case fatality rate (CFR) of COVID-19 is estimated to be lower than for SARS (~10%) and MERS (~35%). However, its basic reproduction number (<italic>R</italic>
<sub>0</sub>) is potentially higher than for SARS (~2&#x02013;3) and MERS (&#x0003c;1). The values for CFR and <italic>R</italic>
<sub>0</sub> of SARS-CoV-2 are still under controversial debate.<xref rid="b0070" ref-type="bibr">14</xref>, <xref rid="b0075" ref-type="bibr">15</xref> Undetected and asymptomatic infections can challenge the accuracy of these parameters.<xref rid="b0080" ref-type="bibr">16</xref>, <xref rid="b0085" ref-type="bibr">17</xref>, <xref rid="b0090" ref-type="bibr">18</xref>, <xref rid="b0095" ref-type="bibr">19</xref> The ongoing COVID-19 pandemic has had an unprecedented impact on individuals and the economy, as travel restrictions, social distancing and quarantine measures were implemented by many countries.<xref rid="b0100" ref-type="bibr">20.</xref>, <xref rid="b0105" ref-type="bibr">21</xref>
</p><p id="p0015">SARS-CoV, MERS-CoV and SARS-CoV-2 belong to the family of <italic>Coronaviridae</italic> and the genus <italic>Betacoronavirus</italic>. Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses that feature the largest known RNA virus genomes ranging approximately from 26 to 32&#x000a0;kb,<xref rid="b0110" ref-type="bibr">22</xref>, <xref rid="b0115" ref-type="bibr">23</xref>, <xref rid="b0120" ref-type="bibr">24.</xref>, <xref rid="b0125" ref-type="bibr">25</xref>, <xref rid="b0130" ref-type="bibr">26</xref> containing at least 6 (14 in case of SARS-CoV-2) open reading frames (ORFs).<xref rid="b0135" ref-type="bibr">27</xref>, <xref rid="b0140" ref-type="bibr">28</xref> The major reading frame ORF 1ab encodes for two overlapping polyproteins (pp1a, pp1ab), which are cleaved into 16 non-structural proteins (nsp1-16) by the main protease M<sup>pro</sup> (also referred to as 3CL<sup>pro</sup>) and the papain-like protease PL<sup>pro</sup> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
).<xref rid="b0135" ref-type="bibr">27</xref>, <xref rid="b0145" ref-type="bibr">29</xref>, <xref rid="b0150" ref-type="bibr">30</xref>, <xref rid="b0155" ref-type="bibr">31</xref>, <xref rid="b0160" ref-type="bibr">32</xref> In addition, the papain-like protease is also a deubiquitinase.<xref rid="b0165" ref-type="bibr"><sup>33</sup></xref> The remainder of the genome encodes for accessory and structural proteins such as the spike glycoprotein (S), envelope protein (E), membrane protein (M) and the nucleocapsid phosphoprotein (N).<xref rid="b0135" ref-type="bibr">27</xref>, <xref rid="b0145" ref-type="bibr">29</xref>, <xref rid="b0150" ref-type="bibr">30</xref>, <xref rid="b0155" ref-type="bibr">31</xref>, <xref rid="b0160" ref-type="bibr">32</xref> The first genome sequence of SARS-CoV-2 deposited in Genbank was from the ~30&#x000a0;kb isolate Wuhan-Hu-1 (MN908947),<xref rid="b0015" ref-type="bibr"><sup>3</sup></xref> which is used for sequence-related analyses in this article.<fig id="f0005"><label>Fig. 1</label><caption><p>(a) Organisation of the RNA genome of SARS-CoV-2 with selected genes (Wuhan-Hu-1 isolate MN908947). (b) Schematic representation of polyprotein cleavage sites of SARS-CoV-2. The papain-like protease PL<sup>pro</sup> cleaves at 3 distinct sites. The main protease M<sup>pro</sup> (also referred to as 3CL<sup>pro</sup>) cleaves at 11 distinct sites.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0020">SARS-CoV-2 is closely related to other viruses of the <italic>Betacoronavirus</italic> genus such as the bat coronavirus BatCoV RaTG13 (~96% sequence identity) and the SARS-CoV (~80% sequence identity).<xref rid="b0170" ref-type="bibr">34</xref>, <xref rid="b0175" ref-type="bibr">35</xref> SARS-CoV and MERS-CoV are both of zoonotic origin, with bats being their natural reservoir. Transmission to humans can occur via their intermediate hosts palm civets (SARS) and dromedary camels (MERS).<xref rid="b0180" ref-type="bibr"><sup>36</sup></xref> SARS-CoV-2 is thought to have followed a similar evolutionary transmission cascade.<xref rid="b0185" ref-type="bibr">37</xref>, <xref rid="b0190" ref-type="bibr">38</xref> The spike glycoprotein (S) plays an important role in host range (tropism) and &#x02018;host jumps&#x02019;.<xref rid="b0195" ref-type="bibr">39</xref>, <xref rid="b0200" ref-type="bibr">40</xref> In the case of SARS-CoV and SARS-CoV-2, it recognises the receptor angiotensin-converting enzyme 2 (ACE 2), which both viruses employ for cell entry.<xref rid="b0205" ref-type="bibr">41</xref>, <xref rid="b0210" ref-type="bibr">42</xref>, <xref rid="b0215" ref-type="bibr">43</xref> Comparisons of structural proteins of SARS-CoV-2, such as the spike protein (S), with those from animal coronaviruses indicate the involvement of bats as natural reservoir with a possibility for pangolins as intermediate hosts.<xref rid="b0190" ref-type="bibr">38</xref>, <xref rid="b0220" ref-type="bibr">44</xref>, <xref rid="b0225" ref-type="bibr">45</xref>, <xref rid="b0230" ref-type="bibr">46</xref>, <xref rid="b0235" ref-type="bibr">47</xref>, <xref rid="b0240" ref-type="bibr">48</xref>, <xref rid="b0245" ref-type="bibr">49</xref> As the introduction of coronaviruses into human population has been observed on multiple occasions, a better understanding of the naturally circulating viruses is of high interest for pandemic prevention as is antiviral research to prepare for future outbreaks.<xref rid="b0250" ref-type="bibr">50</xref>, <xref rid="b0255" ref-type="bibr">51</xref>
</p></sec><sec id="s0010"><title>The main protease as drug target</title><p id="p0025">The current COVID-19 pandemic has triggered global efforts for the rapid identification of vaccines and specific antiviral treatments.<xref rid="b0260" ref-type="bibr">52</xref>, <xref rid="b0265" ref-type="bibr">53</xref>, <xref rid="b0270" ref-type="bibr">54</xref>, <xref rid="b0275" ref-type="bibr">55</xref> Amongst the coronaviral targets that have been studied in the past, the main protease (M<sup>pro</sup>, 3CL<sup>pro</sup>, nsp5) received major attention,<xref rid="b0125" ref-type="bibr">25</xref>, <xref rid="b0280" ref-type="bibr">56</xref> particularly following the first SARS-CoV outbreak in the early 2000s.<xref rid="b0115" ref-type="bibr">23</xref>, <xref rid="b0285" ref-type="bibr">57</xref> Alternative coronaviral targets include the spike protein (S), RNA-dependent RNA-polymerase (RdRp, nsp12), NTPase/helicase (nsp13) and papain-like protease (PL<sup>pro</sup>, part of nsp3).<xref rid="b0250" ref-type="bibr">50</xref>, <xref rid="b0290" ref-type="bibr">58</xref> The papain-like protease also recognises the C-terminal sequence of ubiquitin. Therefore, substrate-derived inhibitors of PL<sup>pro</sup> would be expected to also inhibit host-cell deubiquitinases, making drug-discovery campaigns against PL<sup>pro</sup> challenging. In stark contrast, the main protease M<sup>pro</sup> exclusively cleaves polypeptide sequences after a glutamine residue, positioning the main protease as an ideal drug target because, to the best of our knowledge, no human host-cell proteases are known with this substrate specificity.<xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0300" ref-type="bibr">60</xref>, <xref rid="b0305" ref-type="bibr">61</xref>
</p><p id="p0030">Viral proteases are well validated drug targets that have led to various approved drugs, for example, against chronic infections with human immunodeficiency virus (HIV) or hepatitis C virus (HCV), which employ aspartyl and serine proteases, respectively.<xref rid="b0310" ref-type="bibr"><sup>62</sup></xref> The SARS-CoV-2 M<sup>pro</sup> proteolytically cleaves the overlapping pp1a and pp1ab polyproteins to functional proteins (<xref rid="f0005" ref-type="fig">Fig. 1</xref>), which is a critical step during viral replication.<xref rid="b0145" ref-type="bibr">29</xref>, <xref rid="b0315" ref-type="bibr">63</xref>, <xref rid="b0320" ref-type="bibr">64</xref> Replication-essential enzymes such as RdRp or nsp13 cannot fully function without prior proteolytic release,<xref rid="b0280" ref-type="bibr"><sup>56</sup></xref> positioning M<sup>pro</sup> as a key enzyme in the viral replication cycle. Consequently, its inhibition can stall the production of infectious viral particles and thus alleviate disease symptoms.<xref rid="b0115" ref-type="bibr">23</xref>, <xref rid="b0250" ref-type="bibr">50</xref>, <xref rid="b0325" ref-type="bibr">65</xref>, <xref rid="b0330" ref-type="bibr">66</xref>, <xref rid="b0335" ref-type="bibr">67</xref>, <xref rid="b0340" ref-type="bibr">68</xref> Capitalising on knowledge gained on structure and inhibitors of M<sup>pro</sup> from previous epidemical coronaviruses, M<sup>pro</sup> is one of the most attractive viral targets for antiviral drug discovery against SARS-CoV-2.</p></sec><sec id="s0015"><title>Structure and function of the main protease</title><p id="p0035">Early homology models of SARS-CoV-2 M<sup>pro</sup> indicated close structural relation to other coronaviral main proteases.<xref rid="b0345" ref-type="bibr"><sup>69</sup></xref> Amino acid sequence alignments reveal ~99% identity with BatCoV RaTG13 M<sup>pro</sup> and ~96% with the previous SARS-CoV M<sup>pro</sup>. In contrast, sequence identity with MERS-CoV M<sup>pro</sup> is only ~50% (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
).<fig id="f0010"><label>Fig. 2</label><caption><p>Alignment of the amino acid sequences of crystallised main proteases of SARS-CoV-2 (PDB: 6Y2E), SARS-CoV (PDB: 2BX4) and MERS-CoV (PDB: 5C3N). Domains I, II and III comprise residues 8&#x02013;101, 102&#x02013;184 and 201&#x02013;306, respectively. The catalytic dyads are indicated by asterisks. The alignment was generated using T-Coffee and shaded with Boxshade.</p></caption><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0040">Superimposition of the X-ray crystal structures of the main proteases of SARS-CoV-2, SARS-CoV and MERS-CoV indicates a high degree of structural similarity and conservation of the active site (<xref rid="f0015" ref-type="fig">Fig. 3</xref>
). This might prove valuable for the development of pan-coronaviral drugs and has already been employed for the development of SARS-CoV-2 M<sup>pro</sup> inhibitors that were based on previous compounds targeting the SARS-CoV or MERS-CoV main proteases.<fig id="f0015"><label>Fig. 3</label><caption><p>Superimposition of X-ray crystal structures of the main proteases of SARS-CoV (pink, PDB: 2BX4), MERS-CoV (cyan, PDB: 5C3N) and SARS-CoV-2 (green, PDB: 6Y2E). Only the monomers are shown. Residues of the catalytic dyad are indicated (His41/Cys145 for SARS-CoV and SARS-CoV-2 and His41/Cys148 for MERS-CoV). The root-mean-square deviation (RMSD) of the superimpositions is 0.934&#x000a0;&#x000c5; for SARS-CoV/MERS-CoV, 0.532&#x000a0;&#x000c5; for SARS-CoV/SARS-CoV-2 and 0.905&#x000a0;&#x000c5; for MERS-CoV/SARS-CoV-2. This figure was generated with UCSF Chimera.<xref rid="b0350" ref-type="bibr"><sup>70.</sup></xref></p></caption><graphic xlink:href="gr3_lrg"/></fig></p><p id="p0045">M<sup>pro</sup> is a cysteine protease with a catalytic dyad (cysteine and histidine) in its active centre (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). While other cysteine and serine proteases contain a third catalytic residue, a buried water molecule occupies this place in the active site of M<sup>pro</sup>.<xref rid="b0115" ref-type="bibr">23</xref>, <xref rid="b0125" ref-type="bibr">25</xref>, <xref rid="b0355" ref-type="bibr">71</xref> The proteolytic process is believed to follow a multi-step mechanism. After the cysteine side chain proton is abstracted by the histidine&#x02019;s imidazole, the resulting thiolate nucleophile attacks the amide bond of the substrate. The <italic>N</italic>-terminal peptide product is released by proton abstraction from histidine before the thioester is hydrolysed to release the C-terminal product and restore the catalytic dyad.<xref rid="b0360" ref-type="bibr">72</xref>, <xref rid="b0365" ref-type="bibr">73</xref>
</p><p id="p0050">M<sup>pro</sup> (nsp5) autocleaves itself between nsp4 and nsp6,<xref rid="b0370" ref-type="bibr">74</xref>, <xref rid="b0375" ref-type="bibr">75</xref> before processing the overlapping polyproteins pp1a and pp1ab at 11 cleavage sites (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).<xref rid="b0145" ref-type="bibr">29</xref>, <xref rid="b0315" ref-type="bibr">63</xref>, <xref rid="b0320" ref-type="bibr">64</xref> While the M<sup>pro</sup> monomer is basically inactive, the homodimer is the primary active species with both protomers almost orthogonally aligned to each other (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>
a).<xref rid="b0340" ref-type="bibr">68</xref>, <xref rid="b0360" ref-type="bibr">72</xref> Each protomer consists of three domains (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>b). In case of SARS-CoV and SARS-CoV-2, domains I and II comprise residues 8&#x02013;101 and 102&#x02013;184, respectively, and include an antiparallel &#x003b2;-barrel with similarities to trypsin-like serine proteases.<xref rid="b0285" ref-type="bibr"><sup>57</sup></xref> Domain II is connected to Domain III (residues 201&#x02013;306) via a longer loop region (residues 185&#x02013;200). Domain III is characterised by a cluster of five &#x003b1;-helices.<xref rid="b0285" ref-type="bibr">57</xref>, <xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0380" ref-type="bibr">76</xref>, <xref rid="b0385" ref-type="bibr">77</xref>, <xref rid="b0390" ref-type="bibr">78</xref>, <xref rid="b0395" ref-type="bibr">79</xref>
<fig id="f0020"><label>Fig. 4</label><caption><p>X-ray crystal structure of the M<sup>pro</sup> homodimer of SARS-CoV-2 (PDB: 6Y2E). Residues of the catalytic dyad (His41/Cys145) are indicated. (a) Protomers are indicated. (b) Protomer domains are indicated. This figure has been generated with UCSF Chimera.<xref rid="b0350" ref-type="bibr"><sup>70.</sup></xref></p></caption><graphic xlink:href="gr4_lrg"/></fig></p><p id="p0055">The protomers bind to each other via an <italic>N</italic>-terminal finger (residues 1&#x02013;7) located between domains II and III, which is involved in the formation of the substrate-binding site in a cleft between domains I and II.<xref rid="b0285" ref-type="bibr">57</xref>, <xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0380" ref-type="bibr">76</xref>, <xref rid="b0385" ref-type="bibr">77</xref>, <xref rid="b0390" ref-type="bibr">78</xref> It is known that the mutations Ser284Ala, Thr285Ala and Ile286Ala in SARS-CoV M<sup>pro</sup> result in a 3.6-fold increase in catalytic activity.<xref rid="b0400" ref-type="bibr"><sup>80</sup></xref> Two similar mutations (Thr285Ala and Ile286Leu) are present in SARS-CoV-2 M<sup>pro</sup>, potentially explaining higher activity observed for SARS-CoV-2 M<sup>pro</sup> compared to SARS-CoV M<sup>pro</sup>.<xref rid="b0295" ref-type="bibr"><sup>59</sup></xref> The Thr285Ala mutation is believed to bring domain III of both protomers closer to each other.<xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0395" ref-type="bibr">79</xref>
</p></sec><sec id="s0020"><title>Substrate specificity and inhibitor design</title><p id="p0060">According to the nomenclature introduced by Schechter and Berger,<xref rid="b0405" ref-type="bibr"><sup>81</sup></xref> M<sup>pro</sup> mainly recognises substrate residues ranging from <italic>P</italic>
<sub>4</sub> to <italic>P</italic>
<sub>1</sub>&#x02032;.<xref rid="b0410" ref-type="bibr"><sup>82</sup></xref> Prime site recognition beyond <italic>P</italic>
<sub>1</sub>&#x02032; is not conserved (<xref rid="f0025" ref-type="fig">Fig. 5</xref>
). Specificity is mostly determined by <italic>P</italic>
<sub>1</sub>, <italic>P</italic>
<sub>2</sub> and <italic>P</italic>
<sub>1</sub>&#x02032;, which show the highest degree of conservation amongst the cleavage sites.<xref rid="b0315" ref-type="bibr"><sup>63</sup></xref> Glutamine in <italic>P</italic>
<sub>1</sub> is highly conserved in all polyprotein cleavage sites of SARS-CoV, MERS-CoV and SARS-CoV-2 (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). In <italic>P</italic>
<sub>2</sub> more hydrophobic amino acids are tolerated with a clear preference for leucine. <italic>P</italic>
<sub>1</sub>&#x02032; tolerates small residues like serine or alanine.<xref rid="b0280" ref-type="bibr">56</xref>, <xref rid="b0300" ref-type="bibr">60</xref>, <xref rid="b0305" ref-type="bibr">61</xref>, <xref rid="b0415" ref-type="bibr">83</xref>, <xref rid="b0420" ref-type="bibr">84</xref>, <xref rid="b0425" ref-type="bibr">85</xref> Analysis of all polyprotein cleavage sites processed by M<sup>pro</sup> for SARS-CoV, MERS-CoV and SARS-CoV-2 illustrates very similar substrate recognition profiles amongst these viruses (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). Particularly important is the pronounced preference for glutamine in <italic>P</italic>
<sub>1</sub>, strongly informing inhibitor design.<xref rid="b0420" ref-type="bibr"><sup>84</sup></xref> Since no human host-cell proteases with similar specificity are reported, reduced off-target effects are assumed for peptidomimetic inhibitors.<xref rid="b0300" ref-type="bibr">60</xref>, <xref rid="b0305" ref-type="bibr">61</xref>
<fig id="f0025"><label>Fig. 5</label><caption><p>Polyprotein cleavage sites recognised by M<sup>pro</sup> of SARS-CoV-2, SARS-CoV and MERS-CoV. Peptide sequences cover residues P<sub>5</sub> to P<sub>5</sub>&#x02032; according to the nomenclature of Schechter and Berger.<xref rid="b0405" ref-type="bibr"><sup>81</sup></xref> Data were generated from pp1ab polyprotein sequences reported in the UniProt database with the accession codes P0DTD1 (SARS-CoV-2), P0C6X7 (SARS-CoV) and K9N7C7 (MERS-CoV). The consensus sequence over all cleavage sites was plotted using WebLogo.<xref rid="b0430" ref-type="bibr"><sup>86.</sup></xref></p></caption><graphic xlink:href="gr5_lrg"/></fig></p><p id="p0065">The catalytic dyad of M<sup>pro</sup> is located in a cleft between domains I and II (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>b).<xref rid="b0115" ref-type="bibr">23</xref>, <xref rid="b0355" ref-type="bibr">71</xref> Despite the minor mutation S46A in close proximity, the active sites of SARS-CoV and SARS-CoV-2 M<sup>pro</sup> are highly conserved. The influence of the S46A mutation on shape, size, flexibility and plasticity of the active site and its relevance for inhibitor design is under debate.<xref rid="b0435" ref-type="bibr">87</xref>, <xref rid="b0440" ref-type="bibr">88</xref>
</p><p id="p0070">As the monomer of M<sup>pro</sup> is principally regarded as inactive, the dimerization interface offers an alternative target site for drug discovery.<xref rid="b0340" ref-type="bibr">68</xref>, <xref rid="b0360" ref-type="bibr">72</xref> Although strong dimerization inhibitors are yet unavailable, the principle has been proven with the <italic>N</italic>-terminal octapeptide of SARS-CoV M<sup>pro</sup>.<xref rid="b0445" ref-type="bibr"><sup>89</sup></xref>
</p></sec><sec id="s0025"><title>Inhibitors</title><p id="p0075">Inhibitors of SARS-CoV M<sup>pro</sup> have been reviewed comprehensively by Pillaiyar et al. in 2016.<xref rid="b0360" ref-type="bibr"><sup>72</sup></xref> MERS-CoV inhibitors have been reviewed by Liang et al. in 2018.<xref rid="b0450" ref-type="bibr"><sup>90</sup></xref> Peptidomimetics and small molecules have been reported with affinities in the micro- to nanomolar range. They often depend on warhead-based design strategies, employing different reactive groups to covalently attack the catalytic cysteine residue. Warheads utilised include Michael acceptors, aldehydes, epoxy ketones and other ketones.<xref rid="b0360" ref-type="bibr"><sup>72</sup></xref>
</p><p id="p0080">Although SARS-CoV-2 emerged only very recently, several inhibitors have already been identified and successfully co-crystallised with M<sup>pro</sup> (<xref rid="f0030" ref-type="fig">Fig. 6</xref>
).<xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0395" ref-type="bibr">79</xref>, <xref rid="b0455" ref-type="bibr">91</xref> They are often derived from previous campaigns which targeted the main proteases of SARS-CoV or MERS-CoV and contain cysteine-reactive warheads (<xref rid="f0030" ref-type="fig">Fig. 6</xref>).<fig id="f0030"><label>Fig. 6</label><caption><p>X-ray co-crystal structures of SARS-CoV-2 M<sup>pro</sup> with covalently binding peptidomimetic inhibitors. M<sup>pro</sup> is shown as hydrophobicity surface (red indicating hydrophobic and blue hydrophilic surface areas) and grey ribbon with amino acid side chains (UCSF Chimera).<xref rid="b0350" ref-type="bibr"><sup>70</sup></xref> Inhibitor groups binding to protease subsites are indicated according to the Schechter Berger nomenclature.<xref rid="b0405" ref-type="bibr"><sup>81</sup></xref> Electrophilic warheads covalently binding to Cys145 are circled. (a) Compound <bold>3</bold> with an &#x003b1;-ketoamide warhead (PDB: 6Y2F). (b) Compound <bold>4</bold> with a Michael acceptor warhead (PDB: 7BQY). (c) Compound <bold>5</bold> with a C-terminal aldehyde warhead (PDB: 6LZE).</p></caption><graphic xlink:href="gr6_lrg"/></fig></p><p id="p0085">The first reported inhibitors were covalently binding peptidomimetics (<bold>1</bold>&#x02013;<bold>3</bold>) addressing the major substrate-recognition motif from <italic>P</italic>
<sub>1</sub>&#x02032; to <italic>P</italic>
<sub>3</sub>.<xref rid="b0295" ref-type="bibr"><sup>59</sup></xref> They all comprise an &#x003b1;-ketoamide functionality that forms a hemithioacetal with Cys145. &#x003b1;-Ketoamides are already used as viral serine protease warheads in the approved HCV drugs telaprevir and boceprevir.<xref rid="b0310" ref-type="bibr"><sup>62</sup></xref> Compound <bold>1</bold> has previously been investigated as a broad-spectrum corona- and enteroviral protease inhibitor.<xref rid="b0300" ref-type="bibr"><sup>60</sup></xref> Like many other M<sup>pro</sup> inhibitors, the <italic>P</italic>
<sub>1</sub> side chains of <bold>1</bold>&#x02013;<bold>3</bold> employ a &#x003b3;-lactam as a glutamine mimetic. <italic>P</italic>
<sub>2</sub> comprises hydrophobic cyclohexyl (<bold>1</bold>, <bold>2</bold>) or smaller cyclopropyl (<bold>3</bold>) groups as leucine mimetics and <italic>P</italic>
<sub>1</sub>&#x02032; contains cyclopropyl (<bold>2</bold>) or benzyl (<bold>1</bold>, <bold>3</bold>) residues. Compounds <bold>2</bold> and <bold>3</bold> feature pyridone rings between <italic>P</italic>
<sub>2</sub> and <italic>P</italic>
<sub>3</sub> as well as <italic>N</italic>-terminal Boc groups, which were associated with increased plasma half-life, kinetic solubility and thermodynamic solubility. Pharmacokinetic profiling of <bold>2</bold> and <bold>3</bold> in mice also indicated favourable lung tropism. Compounds <bold>1</bold> and <bold>3</bold> displayed sub-micromolar M<sup>pro</sup> inhibition (<xref rid="f0035" ref-type="fig">Fig. 7</xref>
). Compound <bold>3</bold> is similarly active against the SARS-CoV and MERS-CoV main proteases and inhibits SARS-CoV-2 replication in human Calu3 lung cells.<fig id="f0035"><label>Fig. 7</label><caption><p>Inhibitors of the SARS-CoV-2 main protease M<sup>pro</sup>. IC<sub>50</sub> indicates enzymatic inhibition. EC<sub>50</sub> indicates antiviral activity in cells.</p></caption><graphic xlink:href="gr7_lrg"/></fig></p><p id="p0090">Compound <bold>4</bold> is another peptidomimetic M<sup>pro</sup> inhibitor co-crystallised in complex with SARS-CoV-2 M<sup>pro</sup> (<xref rid="f0030" ref-type="fig">Fig.&#x000a0;6</xref>b).<xref rid="b0395" ref-type="bibr"><sup>79</sup></xref> It originated from previous campaigns targeting SARS-CoV M<sup>pro</sup>.<xref rid="b0460" ref-type="bibr"><sup>92</sup></xref> Its Michael acceptor irreversibly modifies Cys145. Compound <bold>4</bold> shows anti-SARS-CoV-2 activity in Vero cells.</p><p id="p0095">Compounds <bold>5</bold> and <bold>6</bold> are the strongest known SARS-CoV-2 M<sup>pro</sup> inhibitors with inhibition constants in the two-digit nanomolar range. These small peptidomimetics feature an indole moiety at the <italic>N</italic>-terminus (<italic>P</italic>
<sub>3</sub>) and a C-terminal aldehyde warhead which binds covalently to Cys145, as proven by X-ray crystallography (<xref rid="f0030" ref-type="fig">Fig.&#x000a0;6</xref>c).<xref rid="b0455" ref-type="bibr"><sup>91</sup></xref> Similar peptide-aldehydes have previously been explored as inhibitors of SARS-CoV M<sup>pro</sup>.<xref rid="b0465" ref-type="bibr">93</xref>, <xref rid="b0470" ref-type="bibr">94</xref> Compound <bold>5</bold> and the previously investigated &#x003b1;-ketoamides <bold>1</bold> and <bold>2</bold> are structurally identical in <italic>P</italic>
<sub>1</sub> and <italic>P</italic>
<sub>2</sub>; however, <bold>5</bold> inhibits one order of magnitude stronger, which is likely caused by the increased electrophilicity of the aldehyde warhead compared to the more drug-like &#x003b1;-ketoamide. Despite, the high reactivity of the aldehyde function, compounds <bold>5</bold> and <bold>6</bold> displayed sub-micromolar antiviral activity in Vero cells (<xref rid="f0035" ref-type="fig">Fig. 7</xref>). In agreement with compound <bold>3</bold>, the <italic>in vitro</italic> activity of <bold>5</bold> and <bold>6</bold> was one order of magnitude weaker than the direct M<sup>pro</sup> inhibition in the enzymatic assay. Notably, <bold>5</bold> exhibited only low toxicity in animal models despite its aldehyde warhead.<xref rid="b0455" ref-type="bibr"><sup>91</sup></xref>
</p><p id="p0100">A high-throughput screening campaign of a library of approved drugs and clinical candidates revealed six small molecules, ebselen, disulfiram, carmofur, tideglusib, shikonin and PX-12, as inhibitors of SARS-CoV-2 M<sup>pro</sup> (<xref rid="f0035" ref-type="fig">Fig. 7</xref>).<xref rid="b0395" ref-type="bibr"><sup>79</sup></xref> Mass spectrometry experiments showed that ebselen, carmofur and PX-12 covalently modify Cys145. Small covalent modifiers like these may bind unspecifically, a characteristic associated with pan-assay interference compounds (PAINS).<xref rid="b0475" ref-type="bibr"><sup>95</sup></xref> Ebselen showed antiviral activity in Vero cells in the low micromolar range. In case of carmofur, a crystal structure of SARS-CoV-2 M<sup>pro</sup> revealed transfer of the hexylurea side chain to Cys145, forming a hexylcarbamothioate interacting with the S<sub>2</sub> subsite (PDB: 7BUY).<xref rid="b0480" ref-type="bibr"><sup>96</sup></xref>
</p><p id="p0105">Crystal structures of SARS-CoV-2 M<sup>pro</sup> in complex with X77 and baicalein (<xref rid="f0035" ref-type="fig">Fig. 7</xref>) have been deposited in the protein data bank under the accession codes 6W63 and 6M2N, respectively. Notably, both compounds bind non-covalently to the active site. X77 and derivatives have previously been investigated as low-micromolar inhibitors of SARS-CoV M<sup>pro</sup>, where a strong stereochemical bias for the (<italic>R</italic>) enantiomer of the pyridyl side chain has been observed.<xref rid="b0485" ref-type="bibr">97</xref>, <xref rid="b0490" ref-type="bibr">98</xref> In the X-ray co-crystal structure of X77, the aforementioned pyridyl side chain acts as a <italic>P</italic>
<sub>1</sub> mimetic. Baicalein is a flavonoid found in <italic>Scutellaria baicalensis</italic>, a plant used in traditional Chinese medicine.<xref rid="b0495" ref-type="bibr"><sup>99</sup></xref> Several flavonoids and derivatives had previously been reported to inhibit the activity of SARS-CoV M<sup>pro</sup>.<xref rid="b0360" ref-type="bibr">72</xref>, <xref rid="b0500" ref-type="bibr">100</xref>
</p><p id="p0110">A fragment screening has produced several crystal structures of fragments bound to SARS-CoV-2 M<sup>pro</sup>, including covalent modifiers of Cys145.<xref rid="b0505" ref-type="bibr"><sup>101</sup></xref> While the majority of fragments bind to the active site, some bind near the dimer interface of SARS-CoV-2 M<sup>pro</sup>. These fragments may inform the development of small-molecule inhibitors that are not substrate-derived.</p><p id="p0115">While this manuscript was under peer-review, a study assessing known protease inhibitors for their anti-SARS-CoV-2 M<sup>pro</sup> activity was published.<xref rid="b0510" ref-type="bibr"><sup>102</sup></xref> Amongst the compounds that displayed M<sup>pro</sup> inhibition and reduction of cytopathic effect were the &#x003b1;-ketoamides boceprevir (<italic>K</italic>
<sub>i</sub>&#x000a0;=&#x000a0;1.18 &#x003bc;&#x0039c;, EC<sub>50</sub>&#x000a0;=&#x000a0;1.31&#x000a0;&#x003bc;M) and calpain inhibitor XII (<italic>K</italic>
<sub>i</sub>&#x000a0;=&#x000a0;0.13 &#x003bc;&#x0039c;, EC<sub>50</sub>&#x000a0;=&#x000a0;0.49&#x000a0;&#x003bc;M), the peptide-aldehyde calpain inhibitor II (<italic>K</italic>
<sub>i</sub>&#x000a0;=&#x000a0;0.40 &#x003bc;&#x0039c;, EC<sub>50</sub>&#x000a0;=&#x000a0;2.07&#x000a0;&#x003bc;M) and the sulfonate-featured peptide GC-376 (<italic>k</italic>
<sub>2</sub>/<italic>K</italic>
<sub>i</sub>&#x000a0;=&#x000a0;40,800&#x000a0;M<sup>&#x02212;1</sup> s<sup>&#x02212;1</sup>, EC<sub>50</sub>&#x000a0;=&#x000a0;3.37&#x000a0;&#x003bc;M). A crystal structure of SARS-CoV-2 M<sup>pro</sup> in complex with GC-376 was also reported (PDB: 6WTT).</p></sec><sec id="s0030"><title>Conclusion and outlook</title><p id="p0120">The COVID-19 pandemic poses a major challenge to mankind. In view of the magnitude of the current global crisis, numerous attempts to develop vaccines and antiviral treatments are obviously underway. With respect to drug development, the main protease of SARS-CoV-2 stands out as a promising viral target, as it differs significantly from human proteases. Given the conserved structure and specificity of M<sup>pro</sup> amongst SARS-CoV, MERS-CoV and SARS-CoV-2, pan-coronaviral main protease inhibitors might become available. However, in line with previously successful examples like HIV or HCV, the development of novel specific protease inhibitors and their approval will take several years. Although this process will likely take too long to impact on the current COVID-19 crisis, protease inhibitors would be worth pursuing as they may provide specific drugs for upcoming coronavirus outbreaks.</p><p id="p0125">Pharmacodynamic and pharmacokinetic properties of peptidomimetic M<sup>pro</sup> inhibitors like <bold>2</bold>, <bold>3</bold>, <bold>5</bold> or <bold>6</bold> already point into the right direction.<xref rid="b0295" ref-type="bibr">59</xref>, <xref rid="b0455" ref-type="bibr">91</xref> Although peptide-aldehydes have entered clinical trials before (e.g. efegatran),<xref rid="b0515" ref-type="bibr">103</xref>, <xref rid="b0520" ref-type="bibr">104</xref>
<bold>5</bold> and <bold>6</bold> are likely to face challenges during further drug development. The &#x003b1;-ketoamide in <bold>1</bold>&#x02013;<bold>3</bold> or Michael acceptor in <bold>4</bold> are covalent modifiers with precedents in approved drugs (e.g. telaprevir or afatinib).<xref rid="b0310" ref-type="bibr">62</xref>, <xref rid="b0525" ref-type="bibr">105</xref> Potential problems associated with limited drug-likeness of peptidomimetics could be circumvented by pursuing alternative small molecules, which might, for example, be accessible from fragment-based drug discovery campaigns.<xref rid="b0505" ref-type="bibr">101</xref>, <xref rid="b0530" ref-type="bibr">106</xref>
</p><p id="p0130">Repurposing of known drugs can provide an accelerated route to approval, which is likely the only option to address the current COVID-19 crisis. Small molecules like ebselen or carmofur are M<sup>pro</sup> inhibitors with anti-SARS-CoV-2 activity in cells;<xref rid="b0395" ref-type="bibr"><sup>79</sup></xref> however, their thiol reactivity might prove challenging. Repurposing approved protease inhibitors is an alternative approach.<xref rid="b0510" ref-type="bibr"><sup>102</sup></xref> Attempts to repurpose the approved combination of HIV protease inhibitors, ritonavir and lopinavir, was unsuccessful in clinical studies, which is not entirely unexpected, given the differences between the proteases of HIV and SARS-CoV-2.<xref rid="b0535" ref-type="bibr"><sup>107</sup></xref>
</p><p id="p0135">It is likely that SARS-CoV-2 is not the last human coronavirus emerging from animals. It is therefore important to closely monitor virus populations to understand their replication mechanism early on and investigate druggable targets. A sharp decline in research funding had been noted a few years after the first SARS epidemic.<xref rid="b0305" ref-type="bibr"><sup>61</sup></xref> Given the long-term nature of drug discovery projects, this has proven disastrous with respect to the current crisis. Now is the best time to progress protease inhibitors to anti-coronaviral drugs.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0140">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>E.</given-names></name><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Gardner</surname><given-names>L.</given-names></name></person-group><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>Lancet Infect Dis</source><volume>20</volume><issue>5</issue><year>2020</year><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id><pub-id pub-id-type="pmid">32087114</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><volume>382</volume><issue>8</issue><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.-F.-W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.-H.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name></person-group><article-title>The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China</article-title><source>J Autoimmun</source><volume>109</volume><year>2020</year><object-id pub-id-type="publisher-id">102434</object-id><pub-id pub-id-type="doi">10.1016/j.jaut.2020.102434</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.</given-names></name><name><surname>Ni</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><volume>382</volume><issue>18</issue><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>H.</given-names></name><name><surname>Khosrawipour</surname><given-names>V.</given-names></name><name><surname>Kocbach</surname><given-names>P.</given-names></name></person-group><article-title>The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China</article-title><source>J Travel Med</source><volume>27</volume><issue>3</issue><year>2020</year><fpage>taaa037</fpage><pub-id pub-id-type="doi">10.1093/jtm/taaa037</pub-id><pub-id pub-id-type="pmid">32181488</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Da Costa</surname><given-names>V.G.</given-names></name><name><surname>Moreli</surname><given-names>M.L.</given-names></name><name><surname>Saivish</surname><given-names>M.V.</given-names></name></person-group><article-title>The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century</article-title><source>Arch Virol</source><volume>165</volume><issue>7</issue><year>2020</year><fpage>1517</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1007/s00705-020-04628-0</pub-id><pub-id pub-id-type="pmid">32322993</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Paules</surname><given-names>C.I.</given-names></name><name><surname>Marston</surname><given-names>H.D.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>Coronavirus infections&#x02014;more than just the common cold</article-title><source>JAMA</source><volume>323</volume><issue>8</issue><year>2020</year><fpage>707</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.0757</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan</article-title><source>China. <italic>Lancet.</italic></source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Tong</surname><given-names>Q.</given-names></name></person-group><article-title>Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV</article-title><source>J Med Virol</source><volume>92</volume><issue>5</issue><year>2020</year><fpage>491</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1002/jmv.25709</pub-id><pub-id pub-id-type="pmid">32056249</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol</source><volume>24</volume><issue>6</issue><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>N.</given-names></name><name><surname>Viceconte</surname><given-names>G.</given-names></name><name><surname>Ergonul</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Petersen</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19, SARS and MERS: are they closely related?</article-title><source>Clin Microbiol Infect</source><volume>26</volume><year>2020</year><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.026</pub-id><pub-id pub-id-type="pmid">32234451</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV</article-title><source>Int J Infect Dis</source><volume>94</volume><year>2020</year><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.071</pub-id><pub-id pub-id-type="pmid">32247050</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ji</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China</article-title><source>Emerg Infect Dis</source><volume>26</volume><issue>7</issue><year>2020</year><pub-id pub-id-type="doi">10.3201/eid2607.200718</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name><surname>Teleman</surname><given-names>M.D.</given-names></name><name><surname>Heng</surname><given-names>B.H.</given-names></name><name><surname>Earnest</surname><given-names>A.</given-names></name><name><surname>Ling</surname><given-names>A.E.</given-names></name><name><surname>Leo</surname><given-names>Y.S.</given-names></name></person-group><article-title>Asymptomatic SARS coronavirus infection among healthcare workers, Singapore</article-title><source>Emerg Infect Dis</source><volume>11</volume><issue>7</issue><year>2005</year><fpage>1142</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.3201/eid1107.041165</pub-id><pub-id pub-id-type="pmid">16022801</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name><surname>Gautret</surname><given-names>P.</given-names></name></person-group><article-title>Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV) infection: extent and implications for infection control: a systematic review</article-title><source>Travel Med Infect Dis</source><volume>27</volume><year>2019</year><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2018.12.003</pub-id><pub-id pub-id-type="pmid">30550839</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>M.</given-names></name><name><surname>Yokoe</surname><given-names>D.S.</given-names></name><name><surname>Havlir</surname><given-names>D.V.</given-names></name></person-group><article-title>Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>2158</fpage><lpage>2160</lpage><pub-id pub-id-type="doi">10.1056/NEJMe2009758</pub-id><pub-id pub-id-type="pmid">32329972</pub-id></element-citation></ref><ref id="b0100"><label>20.</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name><surname>Freedman</surname><given-names>D.O.</given-names></name></person-group><article-title>Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak</article-title><source>J Travel Med</source><volume>27</volume><issue>2</issue><year>2020</year><fpage>taaa020</fpage><pub-id pub-id-type="doi">10.1093/jtm/taaa020</pub-id><pub-id pub-id-type="pmid">32052841</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Khosrawipour</surname><given-names>V.</given-names></name><name><surname>Lau</surname><given-names>H.</given-names></name><name><surname>Khosrawipour</surname><given-names>T.</given-names></name></person-group><article-title>Failure in initial stage containment of global COVID-19 epicenters</article-title><source>J Med Virol</source><volume>92</volume><year>2020</year><fpage>863</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1002/jmv.25883</pub-id><pub-id pub-id-type="pmid">32297980</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name></person-group><article-title>From SARS to MERS: thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><volume>11</volume><issue>1</issue><year>2019</year><fpage>59</fpage><pub-id pub-id-type="doi">10.3390/v11010059</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Wadhwani</surname><given-names>P.</given-names></name><name><surname>Mesters</surname><given-names>J.R.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Coronavirus main proteinase (3CL<sup>pro</sup>) structure: basis for design of anti-SARS drugs</article-title><source>Science</source><volume>300</volume><issue>5626</issue><year>2003</year><fpage>1763</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1126/science.1085658</pub-id><pub-id pub-id-type="pmid">12746549</pub-id></element-citation></ref><ref id="b0120"><label>24.</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Lau</surname><given-names>S.K.P.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Coronavirus genomics and bioinformatics analysis</article-title><source>Viruses</source><volume>2</volume><issue>8</issue><year>2010</year><fpage>1804</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.3390/v2081803</pub-id><pub-id pub-id-type="pmid">21994708</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>Molecular biology of severe acute respiratory syndrome coronavirus</article-title><source>Curr Opin Microbiol</source><volume>7</volume><issue>4</issue><year>2004</year><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2004.06.007</pub-id><pub-id pub-id-type="pmid">15358261</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat Microbiol</source><volume>5</volume><issue>4</issue><year>2020</year><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J Med Virol</source><volume>92</volume><issue>4</issue><year>2020</year><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D.E.</given-names></name><name><surname>Jang</surname><given-names>G.M.</given-names></name><name><surname>Bouhaddou</surname><given-names>M.</given-names></name></person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name></person-group><article-title>Virus-encoded proteinases and proteolytic processing in the <italic>Nidovirales</italic></article-title><source>J Gen Virol</source><volume>81</volume><issue>4</issue><year>2000</year><fpage>853</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-81-4-853</pub-id><pub-id pub-id-type="pmid">10725411</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source>Adv Virus Res</source><volume>66</volume><year>2006</year><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id><pub-id pub-id-type="pmid">16877062</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Heusipp</surname><given-names>G.</given-names></name><name><surname>Siddell</surname><given-names>S.G.</given-names></name></person-group><article-title>Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase</article-title><source>J Virol</source><volume>71</volume><issue>5</issue><year>1997</year><fpage>3992</fpage><lpage>3997</lpage><pub-id pub-id-type="pmid">9094676</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Khailany</surname><given-names>R.A.</given-names></name><name><surname>Safdar</surname><given-names>M.</given-names></name><name><surname>Ozaslan</surname><given-names>M.</given-names></name></person-group><article-title>Genomic characterization of a novel SARS-CoV-2</article-title><source>Gene Rep</source><volume>19</volume><year>2020</year><object-id pub-id-type="publisher-id">100682</object-id><pub-id pub-id-type="doi">10.1016/j.genrep.2020.100682</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>Y.M.</given-names></name><name><surname>John</surname><given-names>St.S.E.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name></person-group><article-title>The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds</article-title><source>Antiviral Res</source><volume>115</volume><year>2015</year><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.12.015</pub-id><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Wang</surname><given-names>X.-G.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Ceraolo</surname><given-names>C.</given-names></name><name><surname>Giorgi</surname><given-names>F.M.</given-names></name></person-group><article-title>Genomic variance of the 2019-nCoV coronavirus</article-title><source>J Med Virol</source><volume>92</volume><issue>5</issue><year>2020</year><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1002/jmv.25700</pub-id><pub-id pub-id-type="pmid">32027036</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat Rev Microbiol</source><volume>17</volume><issue>3</issue><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Benvenuto</surname><given-names>D.</given-names></name><name><surname>Giovanetti</surname><given-names>M.</given-names></name><name><surname>Ciccozzi</surname><given-names>A.</given-names></name><name><surname>Spoto</surname><given-names>S.</given-names></name><name><surname>Angeletti</surname><given-names>S.</given-names></name><name><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><article-title>The 2019-new coronavirus epidemic: evidence for virus evolution</article-title><source>J Med Virol</source><volume>92</volume><issue>4</issue><year>2020</year><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1002/jmv.25688</pub-id><pub-id pub-id-type="pmid">31994738</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zai</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group><article-title>Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2</article-title><source>J Med Virol</source><volume>92</volume><year>2020</year><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1002/jmv.25731</pub-id><pub-id pub-id-type="pmid">32104911</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV - a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><volume>7</volume><issue>3</issue><year>2009</year><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond</article-title><source>Trends Microbiol</source><volume>23</volume><issue>8</issue><year>2015</year><fpage>468</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2015.06.003</pub-id><pub-id pub-id-type="pmid">26206723</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><issue>6965</issue><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><volume>581</volume><issue>7807</issue><year>2020</year><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Unveiling the origin and transmission of 2019-nCoV</article-title><source>Trends Microbiol</source><volume>28</volume><issue>4</issue><year>2020</year><fpage>239</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2020.02.001</pub-id><pub-id pub-id-type="pmid">32155431</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>K.G.</given-names></name><name><surname>Rambaut</surname><given-names>A.</given-names></name><name><surname>Lipkin</surname><given-names>W.I.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name><name><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nature Med</source><volume>26</volume><issue>4</issue><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak</article-title><source>Curr Biol</source><volume>30</volume><issue>7</issue><year>2020</year><fpage>1346</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2020.03.022</pub-id><pub-id pub-id-type="pmid">32197085</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zai</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Cross-species transmission of the newly identified coronavirus 2019-nCoV</article-title><source>J Med Virol</source><volume>92</volume><issue>4</issue><year>2020</year><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/jmv.25682</pub-id><pub-id pub-id-type="pmid">31967321</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.-Z.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.035</pub-id><pub-id pub-id-type="pmid">32220310</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>S.K.P.</given-names></name><name><surname>Luk</surname><given-names>H.K.H.</given-names></name><name><surname>Wong</surname><given-names>A.C.P.</given-names></name></person-group><article-title>Possible bat origin of severe acute respiratory syndrome coronavirus 2</article-title><source>Emerg Infect Dis</source><volume>26</volume><issue>7</issue><year>2020</year><pub-id pub-id-type="doi">10.3201/eid2607.200092</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name></person-group><article-title>From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses</article-title><source>Antiviral Res</source><volume>100</volume><issue>1</issue><year>2013</year><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.015</pub-id><pub-id pub-id-type="pmid">24012996</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Bi</surname><given-names>Y.-H.</given-names></name><name><surname>Wang</surname><given-names>Q.-H.</given-names></name><name><surname>Chen</surname><given-names>X.-W.</given-names></name><name><surname>Zhang</surname><given-names>Z.-G.</given-names></name><name><surname>Yao</surname><given-names>Y.-G.</given-names></name></person-group><article-title>Zoonotic origins of human coronavirus 2019 (HCoV-19/SARS-CoV-2): why is this work important?</article-title><source>Zool Res</source><volume>41</volume><issue>3</issue><year>2020</year><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.24272/j.issn.2095-8137.2020.031</pub-id><pub-id pub-id-type="pmid">32314559</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>F.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name></person-group><article-title>Controversial treatments: an updated understanding of the coronavirus disease 2019</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25788</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>N.</given-names></name><name><surname>Saville</surname><given-names>M.</given-names></name><name><surname>Hatchett</surname><given-names>R.</given-names></name><name><surname>Halton</surname><given-names>J.</given-names></name></person-group><article-title>Developing COVID-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><volume>382</volume><issue>21</issue><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat Rev Drug Discov</source><volume>19</volume><issue>3</issue><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name></person-group><article-title>Progress and prospects on vaccine development against SARS-CoV-2</article-title><source>Vaccines</source><volume>8</volume><issue>2</issue><year>2020</year><fpage>153</fpage><pub-id pub-id-type="doi">10.3390/vaccines8020153</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Ivanov</surname><given-names>K.A.</given-names></name><name><surname>Putics</surname><given-names>&#x000c1;.</given-names></name></person-group><article-title>Mechanisms and enzymes involved in SARS coronavirus genome expression</article-title><source>J Gen Virol</source><volume>84</volume><issue>9</issue><year>2003</year><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1099/vir.0.19424-0</pub-id><pub-id pub-id-type="pmid">12917450</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name></person-group><article-title>The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</article-title><source>PNAS</source><volume>100</volume><issue>23</issue><year>2003</year><fpage>13190</fpage><lpage>13195</lpage><pub-id pub-id-type="doi">10.1073/pnas.1835675100</pub-id><pub-id pub-id-type="pmid">14585926</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title><source>Acta Pharm Sin B</source><volume>10</volume><issue>5</issue><year>2020</year><fpage>766</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.02.008</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x003b1;-ketoamide inhibitors</article-title><source>Science</source><volume>368</volume><issue>6489</issue><year>2020</year><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id><pub-id pub-id-type="pmid">32198291</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Kusov</surname><given-names>Y.</given-names></name></person-group><article-title>&#x003b1;-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment</article-title><source>J Med Chem</source><volume>63</volume><issue>9</issue><year>2020</year><fpage>4562</fpage><lpage>4578</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01828</pub-id><pub-id pub-id-type="pmid">32045235</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design</article-title><source>FEBS J</source><volume>281</volume><issue>18</issue><year>2014</year><fpage>4085</fpage><lpage>4096</lpage><pub-id pub-id-type="doi">10.1111/febs.12936</pub-id><pub-id pub-id-type="pmid">25039866</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Agbowuro</surname><given-names>A.A.</given-names></name><name><surname>Huston</surname><given-names>W.M.</given-names></name><name><surname>Gamble</surname><given-names>A.B.</given-names></name><name><surname>Tyndall</surname><given-names>J.D.A.</given-names></name></person-group><article-title>Proteases and protease inhibitors in infectious diseases</article-title><source>Med Res Rev</source><volume>38</volume><issue>4</issue><year>2018</year><fpage>1295</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1002/med.21475</pub-id><pub-id pub-id-type="pmid">29149530</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name><surname>Hegyi</surname><given-names>A.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>Conservation of substrate specificities among coronavirus main proteases</article-title><source>J Gen Virol</source><volume>83</volume><issue>3</issue><year>2002</year><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-83-3-595</pub-id><pub-id pub-id-type="pmid">11842254</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Q.-S.</given-names></name><name><surname>Wang</surname><given-names>S.-Q.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>Polyprotein cleavage mechanism of SARS CoV M<sup>pro</sup> and chemical modification of the octapeptide</article-title><source>Peptides</source><volume>25</volume><issue>11</issue><year>2004</year><fpage>1857</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2004.06.018</pub-id><pub-id pub-id-type="pmid">15501516</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P.-H.</given-names></name></person-group><article-title>Characterization and inhibition of SARS-coronavirus main protease</article-title><source>Curr Top Med Chem</source><volume>6</volume><issue>4</issue><year>2006</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.2174/156802606776287090</pub-id><pub-id pub-id-type="pmid">16611148</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name><surname>Steuber</surname><given-names>H.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Recent advances in targeting viral proteases for the discovery of novel antivirals</article-title><source>Curr Top Med Chem</source><volume>10</volume><issue>3</issue><year>2010</year><fpage>323</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.2174/156802610790725470</pub-id><pub-id pub-id-type="pmid">20166951</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Bartlam</surname><given-names>M.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name></person-group><article-title>Drug design targeting the main protease, the Achilles' heel of coronaviruses</article-title><source>Curr Pharm Des</source><volume>12</volume><issue>35</issue><year>2006</year><fpage>4573</fpage><lpage>4990</lpage><pub-id pub-id-type="doi">10.2174/138161206779010369</pub-id><pub-id pub-id-type="pmid">17168763</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name><surname>Grum-Tokars</surname><given-names>V.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Begaye</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name></person-group><article-title>Evaluating the 3C-like protease activity of SARS-coronavirus: recommendations for standardized assays for drug discovery</article-title><source>Virus Res</source><volume>133</volume><issue>1</issue><year>2008</year><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.015</pub-id><pub-id pub-id-type="pmid">17397958</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name><surname>Stoermer</surname><given-names>M.</given-names></name></person-group><article-title>Homology models of coronavirus 2019-nCoV 3CL<sup>pro</sup> protease</article-title><source>ChemRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.26434/chemrxiv.11637294.v3</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>E.F.</given-names></name><name><surname>Goddard</surname><given-names>T.D.</given-names></name><name><surname>Huang</surname><given-names>C.C.</given-names></name></person-group><article-title>UCSF Chimera - a visualization system for exploratory research and analysis</article-title><source>J Comput Chem</source><volume>25</volume><issue>13</issue><year>2004</year><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>B.-L.</given-names></name><name><surname>Cheng</surname><given-names>S.-C.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>T.-Y.</given-names></name><name><surname>Ho</surname><given-names>K.-I.</given-names></name><name><surname>Chou</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus main protease</article-title><source>PLoS ONE</source><volume>10</volume><issue>12</issue><year>2015</year><object-id pub-id-type="publisher-id">e0144865</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144865</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name><name><surname>Namasivayam</surname><given-names>V.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Jung</surname><given-names>S.-H.</given-names></name></person-group><article-title>An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy</article-title><source>J Med Chem</source><volume>59</volume><issue>14</issue><year>2016</year><fpage>6595</fpage><lpage>6628</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id><pub-id pub-id-type="pmid">26878082</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lai</surname><given-names>L.</given-names></name></person-group><article-title>3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism</article-title><source>Biochemistry</source><volume>43</volume><issue>15</issue><year>2004</year><fpage>4568</fpage><lpage>4574</lpage><pub-id pub-id-type="doi">10.1021/bi036022q</pub-id><pub-id pub-id-type="pmid">15078103</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B.</given-names></name><name><surname>Kang</surname><given-names>X.</given-names></name></person-group><article-title>Activation and maturation of SARS-CoV main protease</article-title><source>Protein Cell</source><volume>2</volume><issue>4</issue><year>2011</year><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s13238-011-1034-1</pub-id><pub-id pub-id-type="pmid">21533772</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>T.</given-names></name><name><surname>Kim</surname><given-names>Y.-T.</given-names></name><name><surname>Nishii</surname><given-names>W.</given-names></name><name><surname>Terada</surname><given-names>T.</given-names></name><name><surname>Shirouzu</surname><given-names>M.</given-names></name><name><surname>Yokoyama</surname><given-names>S.</given-names></name></person-group><article-title>Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CL<sup>pro</sup>) from its polyproteins</article-title><source>FEBS J</source><volume>280</volume><issue>9</issue><year>2013</year><fpage>2002</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1111/febs.12222</pub-id><pub-id pub-id-type="pmid">23452147</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>M.-F.</given-names></name><name><surname>Kuo</surname><given-names>C.-J.</given-names></name><name><surname>Chang</surname><given-names>K.-T.</given-names></name></person-group><article-title>Mechanism of the maturation process of SARS-CoV 3CL protease</article-title><source>J Biol Chem</source><volume>280</volume><issue>35</issue><year>2005</year><fpage>31257</fpage><lpage>31266</lpage><pub-id pub-id-type="doi">10.1074/jbc.M502577200</pub-id><pub-id pub-id-type="pmid">15788388</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>C.-Y.</given-names></name><name><surname>Chang</surname><given-names>H.-C.</given-names></name><name><surname>Hsu</surname><given-names>W.-C.</given-names></name><name><surname>Lin</surname><given-names>T.-Z.</given-names></name><name><surname>Lin</surname><given-names>C.-H.</given-names></name><name><surname>Chang</surname><given-names>G.-G.</given-names></name></person-group><article-title>Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease</article-title><source>Biochemistry</source><volume>43</volume><issue>47</issue><year>2004</year><fpage>14958</fpage><lpage>14970</lpage><pub-id pub-id-type="doi">10.1021/bi0490237</pub-id><pub-id pub-id-type="pmid">15554703</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name><surname>Ul Qamar</surname><given-names>M.T.</given-names></name><name><surname>Alqahtani</surname><given-names>S.M.</given-names></name><name><surname>Alamri</surname><given-names>M.A.</given-names></name><name><surname>Chen</surname><given-names>L.-L.</given-names></name></person-group><article-title>Structural basis of SARS-CoV-2 3CL<sup>pro</sup> and anti-COVID-19 drug discovery from medicinal plants</article-title><source>J Pharm Anal</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Structure of M<sup>pro</sup> from COVID-19 virus and discovery of its inhibitors</article-title><source>Nature</source><volume>582</volume><year>2020</year><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Dynamically-driven enhancement of the catalytic machinery of the SARS 3C-like protease by the S284&#x02013;T285-I286/A mutations on the extra domain</article-title><source>PLoS ONE</source><volume>9</volume><issue>7</issue><year>2014</year><object-id pub-id-type="publisher-id">e101941</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0101941</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name><surname>Schechter</surname><given-names>I.</given-names></name><name><surname>Berger</surname><given-names>A.</given-names></name></person-group><article-title>On the size of the active site in proteases. I. Papain</article-title><source>Biochem Biophys Res Commun</source><volume>27</volume><issue>2</issue><year>1967</year><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/s0006-291x(67)80055-x</pub-id><pub-id pub-id-type="pmid">6035483</pub-id></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>T.</given-names></name><name><surname>Takemoto</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>Y.-T.</given-names></name></person-group><article-title>SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity</article-title><source>PNAS</source><volume>113</volume><issue>46</issue><year>2016</year><fpage>12997</fpage><lpage>13002</lpage><pub-id pub-id-type="doi">10.1073/pnas.1601327113</pub-id><pub-id pub-id-type="pmid">27799534</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name></person-group><article-title>The substrate specificity of SARS coronavirus 3C-like proteinase</article-title><source>Biochem Biophys Res Commun</source><volume>329</volume><issue>3</issue><year>2005</year><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.02.061</pub-id><pub-id pub-id-type="pmid">15752746</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Rut</surname><given-names>W.</given-names></name><name><surname>Groborz</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Substrate specificity profiling of SARS-CoV-2 M<sup>pro</sup> protease provides basis for anti-COVID-19 drug design</article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.07.981928</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>K.</given-names></name><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Feng</surname><given-names>Q.</given-names></name></person-group><article-title>Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase</article-title><source>J Biol Chem</source><volume>279</volume><issue>3</issue><year>2004</year><fpage>1637</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310875200</pub-id><pub-id pub-id-type="pmid">14561748</pub-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name><surname>Crooks</surname><given-names>G.E.</given-names></name><name><surname>Hon</surname><given-names>G.</given-names></name><name><surname>Chandonia</surname><given-names>J.-M.</given-names></name><name><surname>Brenner</surname><given-names>S.E.</given-names></name></person-group><article-title>WebLogo: a sequence logo generator</article-title><source>Genome Res</source><volume>14</volume><issue>6</issue><year>2004</year><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1101/gr.849004</pub-id><pub-id pub-id-type="pmid">15173120</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>J.S.</given-names></name><name><surname>Lalonde</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>W.R.</given-names></name></person-group><article-title>Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV</article-title><source>ChemBioChem</source><volume>21</volume><issue>5</issue><year>2020</year><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1002/cbic.202000047</pub-id><pub-id pub-id-type="pmid">32022370</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name><surname>Bz&#x000f3;wka</surname><given-names>M.</given-names></name><name><surname>Mitusi&#x00144;ska</surname><given-names>K.</given-names></name><name><surname>Raczy&#x00144;ska</surname><given-names>A.</given-names></name><name><surname>Samol</surname><given-names>A.</given-names></name><name><surname>Tuszy&#x00144;ski</surname><given-names>J.A.</given-names></name><name><surname>G&#x000f3;ra</surname><given-names>A.</given-names></name></person-group><article-title>Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design</article-title><source>Int J Mol Sci</source><volume>21</volume><issue>9</issue><year>2020</year><fpage>3099</fpage><pub-id pub-id-type="doi">10.3390/ijms21093099</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase</article-title><source>Biochem Biophys Res Commun</source><volume>339</volume><issue>3</issue><year>2006</year><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.11.102</pub-id><pub-id pub-id-type="pmid">16329994</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name></person-group><article-title>Development of small-molecule MERS-CoV inhibitors</article-title><source>Viruses</source><volume>10</volume><issue>12</issue><year>2018</year><fpage>721</fpage><pub-id pub-id-type="doi">10.3390/v10120721</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name></person-group><article-title>Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease</article-title><source>Science</source><volume>368</volume><issue>6497</issue><year>2020</year><fpage>1331</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1126/science.abb4489</pub-id><pub-id pub-id-type="pmid">32321856</pub-id></element-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name></person-group><article-title>Design of wide-spectrum inhibitors targeting coronavirus main proteases</article-title><source>PLoS Biol</source><volume>3</volume><issue>10</issue><year>2005</year><object-id pub-id-type="publisher-id">e324</object-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0030324</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name><surname>Al-Gharabli</surname><given-names>S.I.</given-names></name><name><surname>Shah</surname><given-names>S.T.A.</given-names></name><name><surname>Weik</surname><given-names>S.</given-names></name></person-group><article-title>An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV M<sup>pro</sup>) inhibitors</article-title><source>ChemBioChem</source><volume>7</volume><issue>7</issue><year>2006</year><fpage>1048</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1002/cbic.200500533</pub-id><pub-id pub-id-type="pmid">16688706</pub-id></element-citation></ref><ref id="b0470"><label>94</label><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>George</surname><given-names>S.</given-names></name><name><surname>Schmidt</surname><given-names>M.F.</given-names></name><name><surname>Al-Gharabli</surname><given-names>S.I.</given-names></name><name><surname>Rademann</surname><given-names>J.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease</article-title><source>Antiviral Res</source><volume>92</volume><issue>2</issue><year>2011</year><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.08.001</pub-id><pub-id pub-id-type="pmid">21854807</pub-id></element-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name><surname>Baell</surname><given-names>J.</given-names></name><name><surname>Walters</surname><given-names>M.A.</given-names></name></person-group><article-title>Chemistry: chemical con artists foil drug discovery</article-title><source>Nature</source><volume>513</volume><issue>7519</issue><year>2014</year><fpage>481</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/513481a</pub-id><pub-id pub-id-type="pmid">25254460</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur</article-title><source>Nat Struct Mol Biol</source><volume>27</volume><issue>6</issue><year>2020</year><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0440-6</pub-id><pub-id pub-id-type="pmid">32382072</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>J.</given-names></name><name><surname>Tokars</surname><given-names>V.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease</article-title><source>J Med Chem</source><volume>56</volume><issue>2</issue><year>2013</year><fpage>534</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1021/jm301580n</pub-id><pub-id pub-id-type="pmid">23231439</pub-id></element-citation></ref><ref id="b0490"><label>98</label><mixed-citation publication-type="other" id="h0490">St. John SE, Mesecar AD. Broad-spectrum non-covalent coronavirus protease inhibitors. US20170313685 United States of America: Purdue Research Foundation 2017.</mixed-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name></person-group><article-title>Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease <italic>in vitro</italic></article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.13.038687</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>M.-S.</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3CL protease by flavonoids</article-title><source>J Enzyme Inhib Med Chem</source><volume>35</volume><issue>1</issue><year>2020</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1080/14756366.2019.1690480</pub-id><pub-id pub-id-type="pmid">31724441</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name><surname>Douangamath</surname><given-names>A.</given-names></name><name><surname>Fearon</surname><given-names>D.</given-names></name><name><surname>Gehrtz</surname><given-names>P.</given-names></name></person-group><article-title>Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease</article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.27.118117</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Sacco</surname><given-names>M.D.</given-names></name><name><surname>Hurst</surname><given-names>B.</given-names></name></person-group><article-title>Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</article-title><source>Cell Res</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41422-020-0356-z</pub-id></element-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name><surname>Steinmetzer</surname><given-names>T.</given-names></name><name><surname>Pilgram</surname><given-names>O.</given-names></name><name><surname>Wenzel</surname><given-names>B.M.</given-names></name><name><surname>Wiedemeyer</surname><given-names>S.J.A.</given-names></name></person-group><article-title>Fibrinolysis inhibitors: potential drugs for the treatment and prevention of bleeding</article-title><source>J Med Chem</source><volume>63</volume><issue>4</issue><year>2020</year><fpage>1445</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01060</pub-id><pub-id pub-id-type="pmid">31658420</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name><surname>Bengtson</surname><given-names>J.</given-names></name><name><surname>Adolphson</surname><given-names>M.</given-names></name><name><surname>Brewer</surname><given-names>D.L.</given-names></name></person-group><article-title>Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the promotion of reperfusion in myocardial infarction evolution (PRIME) trial</article-title><source>Am Heart J</source><volume>143</volume><issue>1</issue><year>2002</year><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1067/mhj.2002.119896</pub-id><pub-id pub-id-type="pmid">11773918</pub-id></element-citation></ref><ref id="b0525"><label>105</label><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>P.A.</given-names></name><name><surname>Widen</surname><given-names>J.C.</given-names></name><name><surname>Harki</surname><given-names>D.A.</given-names></name><name><surname>Brummond</surname><given-names>K.M.</given-names></name></person-group><article-title>Covalent modifiers: a chemical perspective on the reactivity of &#x003b1;, &#x003b2;-unsaturated carbonyls with thiols via hetero Michael addition reactions</article-title><source>J Med Chem</source><volume>60</volume><issue>3</issue><year>2017</year><fpage>839</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00788</pub-id><pub-id pub-id-type="pmid">27996267</pub-id></element-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M.F.</given-names></name><name><surname>Isidro-Llobet</surname><given-names>A.</given-names></name><name><surname>Lisurek</surname><given-names>M.</given-names></name></person-group><article-title>Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening</article-title><source>Angew Chem Int Ed</source><volume>47</volume><issue>17</issue><year>2008</year><fpage>3275</fpage><lpage>3278</lpage><pub-id pub-id-type="doi">10.1002/anie.200704594</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19</article-title><source>N Engl J Med</source><volume>382</volume><issue>19</issue><year>2020</year><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref></ref-list><ack id="ak005"><title>Acknowledgement</title><p>C.N. thanks the Australian Research Council for a Discovery Early Career Research Award (DE190100015). S.U. acknowledges a PROMOS scholarship from the German Academic Exchange Service.</p></ack></back></article>